Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.
To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Thromboxane b2
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Tanaka H et al. | Leukotriene (LT)-receptor antagonist is more effective in asthmatic patients with a low baseline ratio of urinary LTE4 to 2,3-dinor-6-keto-prostaglandin (PG)F1alpha. | 1999 | Allergy | pmid:10380781 |
Elissalde MH and Beier RC | Stimulation and release of prostaglandins and thromboxane from macrophages by cotton dust associated lipopolysaccharides. | 1990 | Am Ind Hyg Assoc J | pmid:2270833 |
Andersson T et al. | Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers. | 2012 | Am J Cardiovasc Drugs | pmid:22631032 |
Leese PT et al. | Valdecoxib does not impair platelet function. | 2002 | Am J Emerg Med | pmid:12098171 |
Jung TT and Juhn SK | Prostaglandins in human cholesteatoma and granulation tissue. | 1988 | Am J Otol | pmid:3177602 |
Mehta P et al. | Plasma concentrations of thromboxane and prostacyclin metabolites in patients with bone tumors. | 1985 | Am J Pediatr Hematol Oncol | pmid:2994511 |
Natarajan G et al. | Chorioamnionitis and ontogeny of circulating prostaglandin and thromboxane in preterm infants. | 2008 | Am J Perinatol | pmid:18726836 |
Brown HL et al. | Plasma and amniotic fluid prostacyclin and thromboxane in mild pregnancy-induced hypertension. | 1987 | Am J Perinatol | pmid:3566883 |
Satterfield S et al. | Biochemical markers of compliance in the Physicians' Health Study. | 1990 Sep-Oct | Am J Prev Med | pmid:2268456 |
Ingster LM and Feinleib M | Salicylate intake and cardiovascular disease: Ingster and Feinleib respond to Hu and Willett. | 1998 | Am J Public Health | pmid:9702172 |
Cambria RA et al. | Thromboxane synthetase inhibition decreases polymorphonuclear leukocyte activation following hindlimb ischemia. | 1991 | Am Surg | pmid:1847027 |
Montalescot G et al. | Early thromboxane release during pacing-induced myocardial ischemia with angiographically normal coronary arteries. | 1990 | Am. Heart J. | pmid:2248190 |
Hirsh PD et al. | Influence of blood sampling site and technique on thromboxane concentrations in patients with ischemic heart disease. | 1982 | Am. Heart J. | pmid:7102506 |
Smith EF and Lefer AM | Stabilization of cardiac lysosomal and cellular membranes in protection of ischemic myocardium due to coronary occlusion:efficacy of the nonsteroidal anti-inflammatory agent, naproxen. | 1981 | Am. Heart J. | pmid:7211667 |
Nakashima Y et al. | Sustained-release nifedipine (nifedipine-L) suppresses plasma thromboxane B2 and 6-keto prostaglandin F1 alpha in both young male smokers and nonsmokers. | 1990 | Am. Heart J. | pmid:2353613 |
Ikonomidis I et al. | Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment. | 2005 | Am. Heart J. | pmid:15894964 |
Kishi Y et al. | Inhibition of platelet aggregation by prostacyclin is attenuated after exercise in patients with angina pectoris. | 1992 | Am. Heart J. | pmid:1736562 |
Tomoda H | Development of an experimental model of acute myocardial infarction and the effects of a thromboxane synthetase inhibitor (OKY-046). | 1986 | Am. Heart J. | pmid:3532743 |
Nitz RE and Martorana PA | The activity of molsidomine in experimental models of ischemic cardiac disease. | 1985 | Am. Heart J. | pmid:3919549 |
Buchanan MR et al. | Effect of nafazatrom on platelet function and release: relationship to symptomatic episodes in patients with peripheral vascular disease. | 1987 | Am. Heart J. | pmid:2953219 |
Walinsky P et al. | Thromboxane A2 in acute myocardial infarction. | 1984 | Am. Heart J. | pmid:6485997 |
Rubenstein MD et al. | Platelet activation in clinical coronary artery disease and spasm. | 1981 | Am. Heart J. | pmid:6455912 |
De Caterina R et al. | Inhibition of platelet function during in vivo infusion of isosorbide mononitrates: relationship between plasma drug concentration and hemodynamic effects. | 1990 | Am. Heart J. | pmid:2321506 |
Lorenzoni R et al. | Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. | 2004 | Am. Heart J. | pmid:15215815 |
Buerke M et al. | Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses. | 1995 | Am. Heart J. | pmid:7661062 |
Mehta J et al. | Thromboxane release in coronary artery disease: spontaneous versus pacing-induced angina. | 1984 | Am. Heart J. | pmid:6695662 |
De Servi S et al. | Coronary vasoconstrictor response to cold pressor test in variant angina: lack of relation to intracoronary thromboxane concentrations. | 1987 | Am. Heart J. | pmid:3630891 |
Cotter G et al. | Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? | 2004 | Am. Heart J. | pmid:14760328 |
Mehta J and Mehta P | Prostacyclin and thromboxane A2 production by human cardiac atrial tissues. | 1985 | Am. Heart J. | pmid:3880988 |
Friedrich T et al. | Follow-up of prostaglandin plasma levels after acute myocardial infarction. | 1985 | Am. Heart J. | pmid:3880994 |
O'Connor KM et al. | The effect of thromboxane inhibition on vulnerability to ventricular fibrillation in the acute and chronic feline infarction models. | 1989 | Am. Heart J. | pmid:2929400 |
Zhu BQ and Parmley WW | Modification of experimental and clinical atherosclerosis by dietary fish oil. | 1990 | Am. Heart J. | pmid:2105047 |
Neri Serneri GG et al. | Abnormal cardiocoronary thromboxane A2 production in patients with unstable angina. | 1985 | Am. Heart J. | pmid:3984828 |
O'Connor KM et al. | Effect of thromboxane synthetase inhibition on vulnerability to ventricular arrhythmia following coronary occlusion. | 1986 | Am. Heart J. | pmid:3953390 |
Roy L et al. | Lack of efficacy of nafazatrom, a novel anti-thrombotic compound, in patients with coronary artery disease. | 1985 | Am. Heart J. | pmid:3158183 |
Austin JC et al. | Thromboxane synthetase inhibition reduces ventricular irritability after coronary occlusion and reperfusion. | 1988 | Am. Heart J. | pmid:3344655 |
Yamada Y et al. | Possible mechanism of vascular reocclusion after initially successful thrombolysis with recombinant tissue-type plasminogen activator. | 1991 | Am. Heart J. | pmid:1903579 |
Arora RR et al. | Laser-induced stimulation of thromboxane B2 synthesis in human blood platelets: role of superoxide radicals. | 1993 | Am. Heart J. | pmid:8381256 |
FitzGerald GA et al. | Cigarette smoking and hemostatic function. | 1988 | Am. Heart J. | pmid:3276116 |
Jouve R et al. | Thromboxane B2, 6-keto-PGF1 alpha, PGE2, PGF2 alpha, and PGA1 plasma levels in arteriosclerosis obliterans: relationship to clinical manifestations, risk factors, and arterial pathoanatomy. | 1984 | Am. Heart J. | pmid:6581715 |
Rebuzzi AG et al. | Importance of reperfusion on thromboxane A2 metabolite excretion after thrombolysis. | 1992 | Am. Heart J. | pmid:1539506 |
Hanet C et al. | Myocardial protection by intracoronary nicardipine administration during percutaneous transluminal coronary angioplasty. | 1987 | Am. J. Cardiol. | pmid:2953226 |
Willerson JT et al. | Potential usefulness of combined thromboxane A2 and serotonin receptor blockade for preventing the conversion from chronic to acute coronary artery disease syndromes. | 1990 | Am. J. Cardiol. | pmid:2146868 |
McDaniel HG et al. | Platelet function abnormalities in response to arachidonic acid in the acute phase of myocardial infarction. | 1983 | Am. J. Cardiol. | pmid:6416046 |
De Caterina R et al. | Inhibition of platelet function by injectable isosorbide dinitrate. | 1984 | Am. J. Cardiol. | pmid:6428211 |
Dabaghi SF et al. | Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes after ingestion in normal subjects. | 1994 | Am. J. Cardiol. | pmid:7942533 |
Théroux P et al. | Hemodynamic, platelet and clinical responses to prostacyclin in unstable angina pectoris. | 1990 | Am. J. Cardiol. | pmid:2109927 |
Willerson JT et al. | Conversion from chronic to acute coronary artery disease: speculation regarding mechanisms. | 1984 | Am. J. Cardiol. | pmid:6391133 |
Shen H et al. | Aspirin Resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study). | 2009 | Am. J. Cardiol. | pmid:19660620 |
Timmermans C et al. | Ridogrel in the setting of percutaneous transluminal coronary angioplasty. | 1991 | Am. J. Cardiol. | pmid:1872272 |